By Ingmar Gorman, PhD
- Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
- Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., … & Feduccia, A. A. (2020). Posttraumatic growth after MDMA‐assisted psychotherapy for posttraumatic stress disorder. Journal of Traumatic Stress, 33(2), 161-170.
- Winkler, P., Gorman, I., & Kočárová, R.(2016). Use of LSD by Mental Health Professionals. In Neuropathology of drug addictions and substance misuse (pp. 773-781). Academic Press.
- Gorman, I., (2015) Drug-assisted Psychotherapy. In Ingersoll, R. E., & Rak, C. F. (2015). Psychopharmacology for Mental Health Professionals: An Integrative Approach. Nelson Education.
- Fujáková, M., Páleníček, T., Brunovský, M.,Gorman, I., Tylš, F., Kubešová, A., … & Horáček, J. (2014). The effect of((−)-2-oxa-4-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY379268), anmGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis. Pharmacology Biochemistry and Behavior, 122, 212-221.
- Páleníček, T., Fujáková, M., Brunovský, M.,Horáček, J., Gorman, I., Balíková, M., … & Höschl, C. (2013). Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology, 225(1), 75-93.
- Páleníček, T., Fujáková, M., Brunovský, M.,Balíková, M., Horáček, J., Gorman, I., … & Krajča, V. (2011).Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics. Neuropsychobiology, 63(4), 202-218.
By Elizabeth Nielson, PhD
- McGuire AL, Cohen IG, Sisti D, et al. Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open. 2024;7(6):e2414650. doi:10.1001/jamanetworkopen.2024.14650
- Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., Rogers, U., & Bogenschutz, M. (2023, June 5). Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis. Psychology of Addictive Behaviors. Advance online publication. https://dx.doi.org/10.1037/adb0000935
- Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., . . . Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18), 1637-1648.
- Nielson, E. M. Psychedelics as a Training Experience for Psychedelic Therapists: Drawing on History to Inform Current Practice. Journal of Humanistic Psychology. June 2021. doi:10.1177/00221678211021204
- Gorman, I., Nielson, E.M., Molinar, A., Cassidy, K., & Sabbagh, J. (2021) Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice. Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246
- Tai, S. J.,Nielson, E. M., Lennard-Jones, M., Johanna Ajantaival, R. L., Winzer, R.,Richards, W. A., … & Malievskaia, E. (2021). Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research. Frontiers in Psychiatry, 12, 27.
- Nielson, E. M., May, D. G., Forcehimes, A. A.,& Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology, 9, 132.
- Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies, 2(2), 64-73.
By Jeffrey Guss, MD
- Agin-Liebes, G. I., Malone, T.,Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., … & Ross, S.(2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology, 34(2), 155-166.
- Sloshower, J., Guss, J., Krause, R., Wallace, R. M.,Williams, M. T., Reed, S., & Skinta, M. D. (2020). Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. Journal of Contextual Behavioral Science, 15, 12-19.
- Malone, T. C., Mennenga, S. E., Guss, J., Podrebarac, S.K., Owens, L. T., Bossis, A. P., … & Ross, S. (2018). Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Frontiers in Pharmacology, 9, 256.
- Nielson, E. M., & Guss, J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. Journal of Psychedelic Studies,2(2), 64-73.
- Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N.,Terrana, S., Friedman, H. L., … & Ross, S. (2017). Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology, 57(5), 488-519.
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S.,Devenot, N., Friedman, H. L., … & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. Journal of Humanistic Psychology, 57(4), 354-388.
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone,T., Cohen, B., … & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165-1180.
By Kelan Thomas, PhD
- Thomas, K., & Malcolm, B.(2021). Adverse Effects. Handbook of Medical Hallucinogens, 414.
- Thomas, K., Malcolm, B., & Lastra, D. (2017).Psilocybin-assisted therapy: A review of a novel treatment for psychiatric disorders. Journal of Psychoactive Drugs, 49(5), 446-455.
- Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C.,Abbas, A. I., Hufeisen, S. J., … & Roth, B. L. (2009). Predicting new molecular targets for known drugs. Nature, 462(7270), 175-181.
- Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J.Z., Crowe, M. S., & Matsumoto, R. R. (2016). Dextromethorphan: An update onits utility for neurological and neuropsychiatric disorders. Pharmacology & Therapeutics, 159, 1-22.
By Casey Paleos, PhD
- Mitchell, J.M., Ot’alora G., M., van der Kolk, B. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29, 2473–2480 (2023). https://doi.org/10.1038/s41591-023-02565-4
- Paleos, C. A., & Ross, S. (2013). Ketamine: a light in the darkness. Multidisciplinary Association for Psychedelic Studies Bulletin, Special Edition, Spring, 28-33.
- Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., … & Paleos, C. (2022). At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders, 314, 59-67. https://doi.org/10.1016/j.jad.2022.07.004
- Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021). https://doi.org/10.1038/s41591-021-01336-3
- O’Donnell, K. C., Anderson, B. T., Barrett, F. S., Bogenschutz, M. P., Grob, C. S., Hendricks, P. S., Kelmendi, B., Nayak, S. M., Nicholas, C. R., Paleos, C. A., Stauffer, C. S., & Gukasyan, N. (2024). Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues’ Commentary on Psilocybin-Assisted Therapy. The American journal of psychiatry, 181(1), 74–75. https://doi.org/10.1176/appi.ajp.20230661
- Alpert, M. D., O’Donnell, K. C., Paleos, C. A., Sola, E., Stauffer, C. S., Wagner, A. C., Nicholas, C. R., & Mithoefer, M. C. (2024). Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary. The American journal of psychiatry, 181(1), 76–77. https://doi.org/10.1176/appi.ajp.20230665
By Dan Roberts, MD, MSW
- Zeifman, Richard J; Kettner, Hannes; Pagni, Broc A; Mallard, Austin; Roberts, Daniel E; Erritzoe, David; Ross, Stephen; Carhart-Harris, Robin L. Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Scientific reports. 2023:13(1).
- O’Donnell, Kelley C.; Roberts, Daniel E; Ching, Terence H.W.; Glick, Gianni; Goldway, Noam; Gukasyan, Natalie; Hokansen, Jamila; Kelmendi, Benjamin; Ross, Stephen; Yaden, Mary E.; Pittenger, Christopher. Letter to the Editor: What Is in a Name? The Many Meanings of Psychedelic. Psychedelic medicine (New Rochelle, N.Y.). 2023.
- Traynor, Jenna M; Roberts, Daniel E; Ross, Stephen; Zeifman, Richard; Choi-Kain, Lois. MDMA-Assisted Psychotherapy for Borderline Personality Disorder. Focus : the journal of lifelong learning in psychiatry. 2022:20(4):358-367.
- Kim, Katherine; Roberts, Daniel. Hallucinogen-related disorders. Addiction medicine: A case and evidence-based guide by Avery, Jonathan D [Ed]; Hankins, David [Ed]. Cham, Switzerland: Springer Nature Switzerland AG; Switzerland, 2022. ISBN: 978-3-030-86429-3.
- VanBronkhorst, Sara B; Edwards, Evonne M; Roberts, Daniel E; Kist, Katie; Evans, Darci L; Mohatt, Justin; Blankenship, Kelly. Suicidality Among Psychiatrically Hospitalized Lesbian, Gay, Bisexual, Transgender, Queer, and/or Questioning Youth: Risk and Protective Factors. LGBT health. 2021:8(6):395-403.
- Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam. Psychiatric consequences of nitrous oxide abuse. Current psychiatry. 2021:20(2):E1-E2.
- Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam. Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness. American journal on addictions. 2021:30(3):268-268.
- Benville, Julia; Agin-Liebes, Gabrielle; Roberts, Daniel E.; Lo, Sharon; Ghazal, Leila; Franco-Corso, Silvia J.; Ross, Stephen. Effects of Psilocybin on Suicidal Ideation in Patients With Life-Threatening Cancer. Biological psychiatry. 2021:89(9):S235-S236.
- Roberts, Daniel; Farahmand, Pantea; Wolkin, Adam. Nitrous Oxide Inhalant Use Disorder Preceding Symptoms Concerning for Primary Psychotic Illness. American journal on addictions. 2020:29(6):525-527.
- Vanbronkhorst, Sara B; Roberts, Daniel E; Edwards, Evonne M; Blankenship, Kelly. Diagnosis and Use of Psychotherapy Among Children and Adolescents Prescribed Antipsychotics. Journal of psychiatric practice. 2018:24(5):323-330.
- Mathai, David & Roberts, Daniel & Nayak, Sandeep & Sepeda, Nathan & Lehrner, Amy & Johnson, Matthew & Lowe, Matthew & Jackson, Heather & Garcia-Romeu, Albert. (2023). Shame, guilt and psychedelic experience: Results from a prospective, longitudinal survey of real-world psilocybin use. 10.31234/osf.io/hm6jn.
- VanBronkhorst, Sara & Edwards, Evonne & Roberts, Daniel & Kist, Katie & Evans, Darci & Mahdasian, Alexandra & Blankenship, Kelly. (2017). 4.21 Depression, Suicidality, Substance Use, and Abuse History Among Lesbian, Gay, Bisexual, Transgender, Queer (LGBTQ) Adolescents Who Are Psychiatrically Hospitalized. Journal of the American Academy of Child & Adolescent Psychiatry. 56. S235. 10.1016/j.jaac.2017.09.237.
- Perron, Brian & Glass, Joseph & Ahmedani, Brian & Vaughn, Michael & Roberts, Daniel & Wu, Li-Tzy. (2011). The prevalence and clinical significance of inhalant withdrawal symptoms among a national sample. Substance abuse and rehabilitation. 2011. 69-76. 10.2147/SAR.S14937.
By Xiaojue Hu, MD
- Hu, X. Review of books Third Culture Kids: Growing Up Among Worlds by D. Pollack & R. E. Van Reken, Raising Global Nomads by R. Pascoe, and The Global Nomad’s Guide to University Transition by T. L. Quick. Group 2015; Vol. 39 (2): 173-176.
- Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843–853.